TLDR Deuruxolitinib is approved to treat severe alopecia areata in adults.
Deuruxolitinib, an oral JAK inhibitor, was approved by the FDA in July 2024 for treating severe alopecia areata (AA) in adults, marking it as the third oral JAK inhibitor for this condition alongside baricitinib and ritlecitinib. AA is an autoimmune disease affecting 2% of the US population, driven by CD8 T-cells and involving cytokines like interferon-gamma and interleukin-15, which rely on JAK signaling. The document reviews deuruxolitinib's mechanism of action, clinical efficacy, and safety profile in managing AA.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
